| Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

2024 Philiadelphia, PA, Patient and Family Conference

The conference will occur over two days - Friday, July 19 from 2-7 PM ET and Saturday, July 20 from 8AM - 4 PM ET.

This conference will provide sessions for both adults and children.

At the hotel, parking is valet only and paid by AAMDSIF.

Conference location - The Inn at Penn @ 3600 Sansome Street Philadelphia, PA 19104

Event Date: 
Fri, 07/19/2024 - 2:00pm (EDT) to Sat, 07/20/2024 - 4:00pm (EDT)
Conference Event Type: 

2024 Seattle Patient and Family Conference

The time is now to save your seat for the 2024 Patient and Family Conference in Los Angeles!

Plan to attend on June 22, 2024, in Seattle, WA, in partnership with Fred Hutchinson Cancer Center - Register Here

Conference Location: Fred Hutchinson Cancer Research Center Weintraub Building 1100 Fairview Ave N Seattle, WA 98109
Parking: There is parking in front of the Weintraub Building. 

Register for the 2024 Seattle Patient and Family Conference
Event Date: 
Sat, 06/22/2024 - 7:45am (EDT)
Conference Event Type: 

2024 Los Angeles Patient and Family Conference

2024 Patient and Family Conference in Los Angeles

Recordings will be coming soon!

The conference offered special post-transplant sessions.
Conference Location: Cooper Auditorium @ City of Hope 1500 E. Duarte Rd Duarte, CA 91010
Parking: Lots HV or G The parking lots are next to the Hope Village Hotel located on the Northwest corner of the City of Hope Campus. (Duarte Rd and Village Rd)
Friday Evening Social: 4/12/24 1913 Restaurant 5:30-7:00 PM PT Located inside the Hope Village Hotel Northwest Corner of City of Hope Campus (Duarte Rd and Village Rd) 

Register Now for the 2024 Los Angeles Patient and Family Conference
Event Date: 
Sat, 04/13/2024 - 7:45am (EDT)
Conference Event Type: 

Haploidentical Transplant with Post-Transplant Cyclophosphamide for Acute Myeloid Leukaemia and Myelodysplastic Syndromes Patients: The Role of Previous Lines of Therapy

Author(s): 
Avenoso D, Serpenti F, Slonim LB, Bouziana S, Dazzi F, Hannah G, Kenyon M, Mehra V, Kulasekararaj A, Krishamurthy P, Shah MN, Lionel S, Pagliuca A, Potter V
Primary Author: 
Avenoso D
Journal Title: 
Mediterranean Journal of Hematology and Infectious Diseases
Original Publication Date: 
Jan 2024

Background: Allogeneic haematopoietic stem-cell transplant is an option, potentially curative, for high-risk acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) patients. Post-transplant cyclophosphamide administration allows for the selection of haploidentical donors in patients who are eligible for the procedure but do not have a fully matched donor since it can overcome the HLA barrier.